A study in humans with coronary artery disease identified the mir-558 as differentially expressed in whole blood, where it was downregulated in patients with recurrent myocardial infarction after percutaneous coronary intervention compared to those without recurrent events, with this association remaining significant after false-discovery rate correction [Onuoha et al. DOI:10.1111/cts.13307].